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It is a philosophical dilemma whether knowing one’s 
cancer risk makes it easier or more difficult to navigate 
the complexity of medical decision making (1,2). The 
emergence of genetic testing of known associations between 
certain mutations and the development of cancer over one’s 
lifetime is as close to the “crystal ball” analogy as we have, 
yet understanding one’s risk and acting on the information 
by undergoing more aggressive screening, diagnostic 
interventions, or preventative surgery can contribute to 
physical and psychological stressors that are not easily 
addressed in an outpatient clinic setting (3). Survivorship 
programs for patients undergoing prophylactic bilateral 
mastectomy for BRCA1–2 mutations, early and acute 
menopausal symptoms after, or bowel issues after familial 
adenomatous polyposis (FAP) have attempted to address 
the unique issues that are involved in making the decision 
to undergo prophylactic intervention and recovering from 
surgery short and long term (4-6). A paucity of programs 
targeting familial gastric cancer puts survivorship issues well 
behind what is required to address the particular needs of 
this patient population.
Gastric cancer is the third leading cause of cancer 
mortality worldwide and survival after diagnosis is low (7-9). 
Most patients continue to present with locally advanced 
disease where long term survival is linked to the patient’s 
ability to tolerate both surgery and adjuvant therapy (10-12). 
The morbidity of the surgery directly impacts their ability 
to tolerate adjuvant chemotherapy (13), contributing to 
both the quality and the quantity of life (14). Therefore, 
the ability to identify patients at highest risk would allow 
for prophylactic intervention with the goal of eliminating 
this as a life limiting possibility. With the identification 
of germline e-Cadherin mutations as a strong risk factor 
for diffuse gastric cancer, we are obligated to establish the 
infrastructure for surveillance and genetic counseling that 
address the unique needs of this subset of patients (15,16).
Diagnosis
Guidelines to diagnose gastric cancer are well established, 
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but less relevant to familial gastric cancer (17). In most 
cases of gastric cancer, patients present with upper 
gastrointestinal symptoms of early satiety, pain, and/or 
anemia associated with bleeding (18,19). This prompts an 
upper endoscopy (20). Biopsies are taken of any abnormality 
as well as the background stomach. Four quadrant sampling 
of a gastric ulcer, cold forceps biopsy of a mucosal mass, 
and random biopsies of the background stomach to 
look for H Pylori infection are all used to increase the 
likelihood of getting an accurate diagnosis without the 
need for additional intervention. The major problem with 
this current diagnostic paradigm is that the diagnosis is 
made after symptoms have developed, the cancer is more 
advanced, and few patients survive long-term (21,22).
With a better understanding of germline mutations 
associated with the development of cancer we are given 
the foresight to identify vulnerable patients, provide 
intervention prior to the development of cancer and break 
the cycle of premature death for families at risk (23). The 
objective of this project is to review the unique aspects of 
the diagnosis, surveillance, management, and survivorship 
in hereditary gastric cancer.
Hereditary gastric cancer
Independent of epidemiologic trends is a population of 
patients with hereditary gastric cancer syndromes (24,25). 
Recent improvement in molecular genetics has refined 
our understanding of the mutations causing hereditary 
gastric cancer (26). Since these patients are most often 
asymptomatic, guidelines for surveillance, indications for 
intervention, and long-term quality of life studies are in the 
medical literature (27). To date, the main gene implicated 
in hereditary diffuse gastric cancer (HDGC) syndrome 
is CDH-1 (27). This encodes E-cadherin, a protein that 
is integral to cell-cell adhesions and has been implicated 
in other cancer subtypes, like colorectal cancer (28). The 
International Gastric Cancer Linkage Consortium (IGL) 
developed diagnostic criteria for HDGC that includes at 
least two cases of cancer in first- or second- degree relatives, 
one of which is prior to the age 50, three documented cases 
of gastric cancer regardless of age, diffuse gastric cancer 
in individuals under 40, or individuals with gastric cancer 
and lobular breast cancer in which one cancer is diagnosed 
under the age of 50. The presence of bilateral lobular breast 
cancer may also justify CDH-1 testing. HDGC represents 
1–2% of all gastric cancer with 37% associated with a 
mutation in CDH-1 (29-32).
Genetic counseling
Genetic counseling is an important component in the 
management of families with a probable inheritable risk 
of any cancer (33). For many families, the knowledge of 
linkage between their “genetics” and cancer(s) that have 
taken the lives of loved ones is bittersweet. The reaction to 
the realization that cancer is likely to occur in them and/or 
another family member in a particular timeframe can lead 
to several emotions, including anger, helplessness, sadness, 
anxiety, and fear (34). The role of the genetic counselor 
is central to both an understanding of the risk and to 
establishing relationships between effected family members 
and medical professionals who will help navigate them 
through years of intervention and surveillance (35). These 
relationships, when they work well, become the foundation 
of survivorship.
Patients surveyed on their confidence in endoscopic 
surveillance prior to prophylactic gastrectomy, reported a 
moderate to high level of confidence that if they continued 
to be followed closely, it would increase the chances of 
finding cancer at an earlier and curable stage (36). This 
is contrary to the established evidence of the impact of 
endoscopic surveillance in the setting of HDGC (37,38).
There are two unresolved issues with respect to 
counseling and management of patients with a familial 
predisposition to gastric cancer:
(I). How do we manage families who meet criteria for 
HDGC, but do not harbor a CDH-1 mutation or 
have variant mutations that are of unclear clinical 
significance? The current recommendation is 
ongoing endoscopic surveillance.
(II). How do we counsel families that harbor the 
CDH-1 mutation, but have no established gastric 
or lobular breast cancer in their family history? 
These mutations are most commonly picked up in 
multigene panels evaluating a broader cancer risk, 
mostly in the context of breast cancer risk (39,40). 
There are currently no established guidelines for 
this patient population.
Screening and surveillance
Annual endoscopy is recommended in all patients with a 
documented CDH-1 mutation despite the low likelihood 
of small cancers being discovered by random biopsies 
of otherwise normal looking mucosa (41,42). Chemo 
endoscopy using the application of 0.4% indigo carmine dye 
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to enhance contrast and help locate possible lesions was not 
associated with an improvement in detection of subclinical 
cancers in patients with CDH-1 mutations (43,44). On the 
other hand, it is extremely common to find multifocal intra-
mucosal signet ring cell cancer within the gastric specimen 
after prophylactic gastrectomy further calling into question 
the “value” of routine endoscopic surveillance in an era of 
cost containment in healthcare (45,46). As unsettling as 
this finding is for a young patient, the natural history of 
what are most often T1N0 tumors suggests that it is rare to 
develop tumor recurrence or metastases.
Lobular breast cancer
Guidel ines for the screening and survei l lance of 
breast cancer are rooted in the BRCA1/2 families and 
mammograms +/− breast MRI depending on the density 
of the breast tissue in younger women (47). In contrast 
to invasive ductal carcinoma that arises in the setting of 
BRCA1/2 carriers, the invasive lobular carcinoma associated 
with the loss of e-cadherin in CDH-1 deficient families 
is more difficult to pick up on mammograms (15,48-50). 
The tumor cells grow in sheets and cords and are less likely 
to form a mass or have associated calcifications (49). The 
current recommendation for screening and surveillance 
of female CDH-1 mutation carriers is bilateral breast 
MRI beginning at 30 (51). The potential value of bilateral 
prophylactic mastectomy has not been established and 
therefore no guideline or recommendation currently 
exists (4). An established relationship with a breast 
oncologist or breast surgeon is important to provide 
comprehensive annual breast examinations, routine 
discussions on breast awareness, and adequate interpretation 
of breast imaging over what is often years of follow-up on a 
case by case basis (52,53).
Prophylactic gastrectomy for hereditary gastric 
cancer
The cumulative risk for diffuse gastric cancer in CDH-
1 mutation carriers is approximately 67% for men and 
83% for women, and in women there is a 42% risk of 
lobular breast cancer (41). Given this high life-time risk 
of developing gastric cancer combined with the high 
mortality associated with established gastric cancer and 
the lack of effective screening, 2016 guidelines issued 
by the international gastric cancer linkage consortium 
recommended that individuals over the age of 20 who 
harbor the CDH-1 mutation undergo prophylactic total 
gastrectomy (54). The NCCN guidelines recommend 
consideration of surgery in affected patients between 18–40 
taking into consideration the age(s) of family members 
who have been treated for gastric cancer (54). Taking 
age at diagnosis into consideration, a conservative 
recommendation is to discuss prophylactic gastrectomy 
5 years earlier than the youngest cancer diagnosis within 
the family.
The major shift toward recommending early and 
prophylactic gastrectomy is born out of the following 
realities:
(I). HDGC that is diagnosed in the context of 
symptoms is rarely cured.
(II). If gastrectomy is performed in CDH-1 patients 
over the age of 40, there is only a 10% chance of 
cure.
(III). Preoperative endoscopies are insufficient to find 
indolent cancers in HDGC patients. In gastrectomy 
specimens, done in the prophylactic setting, 27% 
had evidence of diffuse cancer despite a negative 
surveillance endoscopy.
Since patients are often asymptomatic, the decision to 
undergo total gastrectomy is difficult. Total gastrectomy, 
even when performed in younger and healthier patients, is 
associated with a moderate risk of perioperative morbidity 
as well as long term behavior and dietary modification to 
minimize post gastrectomy symptoms of diarrhea, dumping 
syndrome, weight loss, dysphagia, and reflux (46,55). For 
this reason, it is important for multidisciplinary gastric 
cancer programs to develop the infrastructure to address 
the broader needs of this patient population as they navigate 
the decision-making process, treatment, and survivorship.
Quality of l i fe considerations after total 
gastrectomy
With the introduction of prophylactic surgery for familial 
cancer syndromes, there is increasing attention on the long-
term sequelae of preventative surgery, including quality of 
life studies that cover both the physical and psychosocial 
outcomes for patients after total gastrectomy. Patients 
considering gastrectomy should be given educational 
materials that will put the short term and long-term quality 
of life issues in perspective, namely:
(I). Global quality of life scores, measured on the 
EORTC-QLQ-C30, declined immediately post-
surgery and returned to baseline by 12 months in 
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most patients (56). The majority of issues describe 
by patients were included in the established post 
gastrectomy guidelines and included the dietary 
and behavior modifications recommended to 
minimize intestinal symptoms (51).
(II). Quality of life scores declined again at 24 months 
and the issues that patients encounter are less likely 
to be addressed within the context of an outpatient 
oncology clinic and are often put onto the shoulders 
of community based primary medical doctors. 
At 24-months, most patients reported 2–3 single 
item symptoms including insomnia, appetite loss, 
dyspnea, and diarrhea (38%) (56). Gastrectomy 
related symptoms experienced by patients 2 years 
after surgery included eating restrictions, pain with 
eating, reflux, dysphagia, and dry mouth (56). With 
this information at hand, multi-provider gastric 
programs should include survivorship programs 
that set short term and longer-term expectations 
preoperatively, develop the infrastructure to 
address quality issues peri-operatively, and establish 
community-based partnerships that will ensure that 
we identify and address long term quality of life 
concerns.
(III). One-half of patients express some degree of regret 
2–4 weeks postoperatively. However, most patients 
who expressed regret had these feelings decrease to 
zero or near zero over time (57).
As difficult as it is to digest the inevitability of developing 
cancer, identification of genetic mutations associated with 
familial cancers is actually a blessing to many patients who 
have seen generations of loved ones die prematurely of 
gastric cancer. Our understanding of the natural history 
of this disease and our acceptance of the limitations of our 
surveillance methods has made recommendations far less 
debatable. With our ability to establish risk in an identifiable 
patient population comes opportunity to investigate 
methods to delay or prevent the disease, improve methods 
of surveillance in high risk families, and develop far better 
infrastructure for survivorship in patients after gastrectomy.
Conclusions
The emergence of sophisticated methods to identify 
patients at high risk for the development of gastric cancer 
has given us an opportunity to eliminate a lethal disease in 
an identifiable patient population. Like many familial cancer 
syndromes, the discovery of a CDH-1 mutation in one’s 
family is bittersweet. Guidelines and recommendations 
have been established and prophylactic total gastrectomy 
is considered the most effective treatment. This requires 
substantial physical and emotional investment and lifelong 
dietary and behavior modification. It is imperative that 
patients and their relatives are rooted in programs that 
can address genetic counseling, ongoing surveillance, and 
survivorship.
Acknowledgements
This work is funded by Indiana University Health Oncology 
Programmatic Enhancement Funding to M Maluccio.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare. 
References
1. Ewer MS. Philosophy of care, decision making, and ethical 
considerations. Crit Care Clin 1989;5:679-95.
2. Allen D. Genetic Testing: How Genetics and Genomics 
Can Affect Healthcare Disparities. Clin J Oncol Nurs 
2018;22:116-8.
3. Sunstein CR. Get Ready for a Future With a Genetic 
Crystal Ball. Bloomberg Opinion. 2018 June 1, 2018.
4. Henry DA, Lee MC, Almanza D, et al. Trends in use of 
bilateral prophylactic mastectomy vs high-risk surveillance 
in unaffected carriers of inherited breast cancer syndromes 
in the Inherited Cancer Registry (ICARE). Breast Cancer 
Res Treat 2018. [Epub ahead of print].
5. Shuster LT, Gostout BS, Grossardt BR, et al. Prophylactic 
oophorectomy in premenopausal women and long-term 
health. Menopause Int 2008;14:111-6.
6. Melnitchouk N, Saadat LV, Bleday R, et al. A Decision 
Analysis for Rectal-Sparing Familial Adenomatous 
Polyposis: Total Colectomy With Ileorectal Anastomosis 
Versus Proctocolectomy With IPAA. Dis Colon Rectum 
2019;62:27-32.
7. Venerito M, Vasapolli R, Rokkas T, et al. Gastric cancer: 
epidemiology, prevention, and therapy. Helicobacter 
2018;23 Suppl 1:e12518.
8. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: 
epidemiology, prevention, classification, and treatment. 
Cancer Manag Res 2018;10:239-48.
9. Amin MB, Greene FL, Edge SB, et al. The Eighth 
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:14tgh.amegroups.com
Page 5 of 6Translational Gastroenterology and Hepatology, 2019
Edition AJCC Cancer Staging Manual: Continuing 
to build a bridge from a population-based to a more 
“personalized” approach to cancer staging. CA Cancer J 
Clin 2017;67:93-9.
10. Orditura M, Galizia G, Sforza V, et al. Treatment of 
gastric cancer. World J Gastroenterol 2014;20:1635-49.
11. Ilson DH. Current Progress in the Adjuvant Treatment of 
Gastric Cancer. Surg Oncol Clin N Am 2017;26:225-39.
12. Ozden S, Ozgen Z, Ozyurt H, et al. Survival in gastric 
cancer in relation to postoperative adjuvant therapy and 
determinants. World J Gastroenterol 2015;21:1222-33.
13. Park SH, Kim DY, Heo JS, et al. Postoperative 
chemoradiotherapy for gastric cancer. Ann Oncol 
2003;14:1373-7.
14. Kong H, Kwon OK, Yu W. Changes of quality of life after 
gastric cancer surgery. J Gastric Cancer 2012;12:194-200.
15. Liu X, Chu KM. E-cadherin and gastric cancer: 
cause, consequence, and applications. Biomed Res Int 
2014;2014:637308.
16. Abbas M, Faggian A, Sintali DN, et al. Current and future 
biomarkers in gastric cancer. Biomed Pharmacother 
2018;103:1688-700.
17. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: 
ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 2016;27:v38-v49.
18. Davis MP, Walsh D, Lagman R, et al. Early satiety 
in cancer patients: a common and important but 
underrecognized symptom. Support Care Cancer 
2006;14:693-8.
19. Reyes Lopez A, Gomez Camacho F, Galvez Calderon C, et 
al. Iron-deficiency anemia due to chronic gastrointestinal 
bleeding. Rev Esp Enferm Dig 1999;91:345-58.
20. Muto M, Yao K, Kaise M, et al. Magnifying endoscopy 
simple diagnostic algorithm for early gastric cancer 
(MESDA-G). Dig Endosc 2016;28:379-93.
21. Boldys H, Marek TA, Wanczura P, et al. Even young 
patients with no alarm symptoms should undergo 
endoscopy for earlier diagnosis of gastric cancer. 
Endoscopy 2003;35:61-7.
22. Dahdaleh FS, Turaga KK. Evolving Treatment Strategies 
and Outcomes in Advanced Gastric Cancer with Peritoneal 
Metastasis. Surg Oncol Clin N Am 2018;27:519-37.
23. Sahasrabudhe R, Lott P, Bohorquez M, et al. Germline 
Mutations in PALB2, BRCA1, and RAD51C, Which 
Regulate DNA Recombination Repair, in Patients With 
Gastric Cancer. Gastroenterology 2017;152:983-6 e6.
24. Monahan KJ, Hopkins L. Diagnosis and Management of 
Hereditary Gastric Cancer. Recent Results Cancer Res 
2016;205:45-60.
25. Colvin H, Yamamoto K, Wada N, et al. Hereditary 
Gastric Cancer Syndromes. Surg Oncol Clin N Am 
2015;24:765-77.
26. Huynh JM, Laukaitis CM. Panel testing reveals nonsense 
and missense CDH1 mutations in families without 
hereditary diffuse gastric cancer. Mol Genet Genomic 
Med 2016;4:232-6.
27. Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of 
endoscopic surveillance in hereditary diffuse gastric cancer 
according to CDH1 mutation status. Gastrointest Endosc 
2018;87:408-18.
28. Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in 
contact inhibition and cancer. Oncogene 2018;37:4769-80.
29. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis 
shows that prevalence of Epstein-Barr virus-positive 
gastric cancer differs based on sex and anatomic location. 
Gastroenterology 2009;137:824-33.
30. Camargo MC, Murphy G, Koriyama C, et al. 
Determinants of Epstein-Barr virus-positive gastric 
cancer: an international pooled analysis. Br J Cancer 
2011;105:38-43.
31. Camargo MC, Kim WH, Chiaravalli AM, et al. Improved 
survival of gastric cancer with tumour Epstein-Barr 
virus positivity: an international pooled analysis. Gut 
2014;63:236-43.
32. Camargo MC, Koriyama C, Matsuo K, et al. Case-case 
comparison of smoking and alcohol risk associations with 
Epstein-Barr virus-positive gastric cancer. Int J Cancer 
2014;134:948-53.
33. McCuaig JM, Armel SR, Care M, et al. Next-Generation 
Service Delivery: A Scoping Review of Patient Outcomes 
Associated with Alternative Models of Genetic Counseling 
and Genetic Testing for Hereditary Cancer. Cancers (Basel) 
2018;10.
34. Rauscher EA. Investigating Uncertainty in Genetic 
Counseling Encounters: Managing Information About 
Genetic Cancer Risk. J Health Commun 2017;22:896-904.
35. Lara-Otero K, Weil J, Guerra C, et al. Genetic Counselor 
and Healthcare Interpreter Perspectives on the Role 
of Interpreters in Cancer Genetic Counseling. Health 
Commun 2018:1-11.
36. Li J, Hart TL, Aronson M, et al. Cancer Worry, Perceived 
Risk and Cancer Screening in First-Degree Relatives of 
Patients with Familial Gastric Cancer. J Genet Couns 
2016;25:520-8.
37. Choi IJ. Endoscopic gastric cancer screening and 
surveillance in high-risk groups. Clin Endosc 
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:14tgh.amegroups.com
Page 6 of 6 Translational Gastroenterology and Hepatology, 2019
2014;47:497-503.
38. Tan RY, Ngeow J. Hereditary diffuse gastric cancer: What 
the clinician should know. World J Gastrointest Oncol 
2015;7:153-60.
39. Yannakou CK, Jones K, Ryland GL, et al. Incidental 
detection of germline variants of potential clinical 
significance by massively parallel sequencing in 
haematological malignancies. J Clin Pathol 2018;71:84-7.
40. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive 
Prenatal Testing and Incidental Detection of Occult 
Maternal Malignancies. JAMA 2015;314:162-9.
41. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric 
cancer: diagnosis and management. Clin Gastroenterol 
Hepatol 2006;4:262-75.
42. Fujita H, Lennerz JK, Chung DC, et al. Endoscopic 
surveillance of patients with hereditary diffuse gastric 
cancer: biopsy recommendations after topographic 
distribution of cancer foci in a series of 10 CDH1-mutated 
gastrectomies. Am J Surg Pathol 2012;36:1709-17.
43. Huneburg R, Marwitz T, van Heteren P, et al. 
Chromoendoscopy in combination with random biopsies 
does not improve detection of gastric cancer foci in 
CDH1 mutation positive patients. Endosc Int Open 
2016;4:E1305-E10.
44. Kitagawa Y, Hara T, Ikebe D, et al. Magnified endoscopic 
observation of small depressed gastric lesions using linked 
color imaging with indigo carmine dye. Endoscopy 
2018;50:142-7.
45. Strong VE, Gholami S, Shah MA, et al. Total Gastrectomy 
for Hereditary Diffuse Gastric Cancer at a Single 
Center: Postsurgical Outcomes in 41 Patients. Ann Surg 
2017;266:1006-12.
46. Pantelis D, Lingohr P, Hueneburg R, et al. [Outcomes 
after Prophylactic Total Gastrectomy for Hereditary 
Diffuse Gastric Cancer]. Zentralbl Chir 2018.
47. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-
Associated Hereditary Breast and Ovarian Cancer. In: 
Adam MP, Ardinger HH, Pagon RA et al., editors. 
GeneReviews((R)). Seattle (WA)1993.
48. Oliveira TM, Elias J Jr, Melo AF, et al. Evolving concepts 
in breast lobular neoplasia and invasive lobular carcinoma, 
and their impact on imaging methods. Insights Imaging 
2014;5:183-94.
49. McCart Reed AE, Kutasovic JR, Lakhani SR, et al. 
Invasive lobular carcinoma of the breast: morphology, 
biomarkers and 'omics. Breast Cancer Res 2015;17:12.
50. Hamilton LJ, Evans AJ, Wilson AR, et al. Breast imaging 
findings in women with BRCA1- and BRCA2-associated 
breast carcinoma. Clin Radiol 2004;59:895-902.
51. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary 
diffuse gastric cancer: updated clinical guidelines with an 
emphasis on germline CDH1 mutation carriers. J Med 
Genet 2015;52:361-74.
52. Pass HA, Klimberg SV, Copeland EM, 3rd. Are “breast-
focused” surgeons more competent? Ann Surg Oncol 
2008;15:953-5.
53. Hatcher MB, Fallowfield L, A'Hern R. The psychosocial 
impact of bilateral prophylactic mastectomy: prospective 
study using questionnaires and semistructured interviews. 
BMJ 2001;322:76.
54. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, 
Version 3.2016, NCCN Clinical Practice Guidelines in 
Oncology. J Natl Compr Canc Netw 2016;14:1286-312.
55. Masuzawa T, Takiguchi S, Hirao M, et al. Comparison 
of perioperative and long-term outcomes of total 
and proximal gastrectomy for early gastric cancer: a 
multi-institutional retrospective study. World J Surg 
2014;38:1100-6.
56. Kobayashi D, Kodera Y, Fujiwara M, et al. Assessment of 
quality of life after gastrectomy using EORTC QLQ-C30 
and STO22. World J Surg 2011;35:357-64.
57. Jeong A, An JY. The moderating role of social support on 
depression and anxiety for gastric cancer patients and their 
family caregivers. PLoS One 2017;12:e0189808.
doi: 10.21037/tgh.2019.01.13
Cite this article as: Skill N, Maluccio M. Contemporary 
paradigm for the evaluation and treatment of hereditary gastric 
cancer. Transl Gastroenterol Hepatol 2019;4:14. 
